Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Free Cash Flow (2019 - 2025)

Revolution Medicines has reported Free Cash Flow over the past 7 years, most recently at -$274.7 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$274.7 million for Q4 2025, down 85.63% from a year ago — trailing twelve months through Dec 2025 was -$899.6 million (down 58.45% YoY), and the annual figure for FY2025 was -$899.6 million, down 58.45%.
  • Free Cash Flow for Q4 2025 was -$274.7 million at Revolution Medicines, down from -$205.8 million in the prior quarter.
  • Over the last five years, Free Cash Flow for RVMD hit a ceiling of -$37.0 million in Q3 2021 and a floor of -$274.7 million in Q4 2025.
  • Median Free Cash Flow over the past 5 years was -$84.8 million (2022), compared with a mean of -$110.7 million.
  • Biggest five-year swings in Free Cash Flow: dropped 12.87% in 2023 and later crashed 153.24% in 2024.
  • Revolution Medicines' Free Cash Flow stood at -$40.4 million in 2021, then crashed by 72.69% to -$69.8 million in 2022, then crashed by 81.77% to -$127.0 million in 2023, then decreased by 16.56% to -$148.0 million in 2024, then crashed by 85.63% to -$274.7 million in 2025.
  • The last three reported values for Free Cash Flow were -$274.7 million (Q4 2025), -$205.8 million (Q3 2025), and -$221.9 million (Q2 2025) per Business Quant data.